Search Results

237 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 16

    Selected harmful or potentially harmful constituent yields in the aerosol of commercial closed systems electronic cigarettes

    KORNELIOU A.; JACCARD G.; BELUSHKIN M.; TAFIN DJOKO D.; ESPOSITO M.; JEANNET C.; LAZZERINI M.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Over the past few years, electronic cigarettes have rapidly evolved and have been introduced in multiple markets across the world. They are thought to be a potentially less harmful alternative to cigarettes, as they heat a liquid to generate the...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 41

    Human chemical signature – investigation on the influence of human presence and selected activities on concentrations of airborne constituents

    MITOVA M.I.; GOUJON-GINGLINGER C.; ROTACH M.; MAEDER S.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Available indoor air quality (IAQ) studies on tobacco- and nicotine-containing potentially reduced-risk products (PRRPs), such as electrically heated tobacco products and e-cigarettes, demonstrate substantial reduction of environmental emissions...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs)....
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 47

    A high-throughput and sensitive bioanalytical method for quantification of nicotine and cotinine in rat/mouse plasma using reversed-phase liquid chromatography–tandem mass spectrometry and its application in inhalation study sample analysis

    SAXENA A.(1); ZHANG Chunyan(1); CIPUTRA T.(1); CHNG Yun Xuan(1); PHILLIPS B.(1); VANSCHEEUWIJCK P.(2)
    (1) PMI R&D, Philip Morris International Research Laboratories Pte. Ltd., Singapore; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Nicotine and cotinine are used as primary biomarkers to estimate the exposure of reduced-risk products, such as e-liquids/heated tobacco products, in comparison with cigarettes. The objective of this study was to develop and validate a method per...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 51

    Examining the impact of very low nicotine content (VLNC) on cigarette use patterns – a review of current evidence and suggestions for further research

    SHERWOOD N.
    Neil Sherwood Consulting, Nyon, Switzerland
    A number of scientists and regulatory bodies have called for a reduction in the nicotine content of cigarettes to a minimally addictive level in the expectation that there will be a subsequent increase in the number of smokers who quit and a...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 41

    Sharing and reusing data: toxicology assessment meta-analysis of various e-liquids and heat-not-burn platforms with INTERVALS datasets

    STAN A.; BOUÉ S.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Extensive scientific studies are conducted to assess the relative risks of various candidate modified risk tobacco products compared with those of smoking cigarettes. As the scientific community conducts such assessments for diverse products and in a...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 57

    Cross-cultural equivalence of the ABOUT™–Perceived Risk instrument in seven languages

    CHREA C.(1); CANO S.(2); SALZBERGER T.(3); MAINY N.(1); ACQUADRO C.(4); POPIELNICKI A.(5); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Modus Outcomes, Letchworth Garden City, U.K.; (3) University of Economics and Business, Vienna, Austria; (4) Mapi Research Trust, ICON plc, Lyon, France; (5) TransPerfect, Linguistic Validation Group, Boston, MA, U.S.A.
    The risk of smoking has long been well understood by consumers. However, it is important to measure the perceived risks by consumers of novel smoke-free alternatives to cigarettes. The ABOUT™–Perceived Risk instrument was developed to allow the...